FR1317860A
(es)
|
1961-03-20 |
1963-05-08 |
|
|
DD150456A5
(de)
|
1979-03-01 |
1981-09-02 |
Ciba Geigy Ag |
Verfahren zur herstellung von derivaten des 3-amino-1,2-propandiols
|
DE2951400A1
(de)
|
1979-12-20 |
1981-07-02 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von n,n'-diarylaethylendiaminen oder n, n',n''-triaryldiaethylen-triaminen
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
DK196688A
(da)
*
|
1987-04-28 |
1988-10-29 |
Fujisawa Pharmaceutical Co |
Bicykliske forbindelser og fremgangsmaade til fremstilling deraf
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5676978A
(en)
|
1989-02-14 |
1997-10-14 |
Amira, Inc. |
Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent
|
US5324731A
(en)
|
1989-02-14 |
1994-06-28 |
Amira, Inc. |
Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated
|
US6040138A
(en)
|
1995-09-15 |
2000-03-21 |
Affymetrix, Inc. |
Expression monitoring by hybridization to high density oligonucleotide arrays
|
US5215882A
(en)
|
1989-11-30 |
1993-06-01 |
Ortho Diagnostic Systems, Inc. |
Method of immobilizing nucleic acid on a solid surface for use in nucleic acid hybridization assays
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
US5837832A
(en)
|
1993-06-25 |
1998-11-17 |
Affymetrix, Inc. |
Arrays of nucleic acid probes on biological chips
|
CA2111503A1
(en)
|
1993-12-15 |
1995-06-16 |
Mcgill University |
Apolipoprotein e polymorphism and alzheimer's disease
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
US5707807A
(en)
|
1995-03-28 |
1998-01-13 |
Research Development Corporation Of Japan |
Molecular indexing for expressed gene analysis
|
US5843974A
(en)
|
1995-06-06 |
1998-12-01 |
Eli Lilly And Company |
Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
|
US5958342A
(en)
|
1996-05-17 |
1999-09-28 |
Incyte Pharmaceuticals, Inc. |
Jet droplet device
|
US6060240A
(en)
|
1996-12-13 |
2000-05-09 |
Arcaris, Inc. |
Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
|
US5945289A
(en)
|
1996-12-20 |
1999-08-31 |
Lehrer; Steven |
Method for detecting prostate cancer by apolipoprotein E (Apo-E) genotyping
|
US6090556A
(en)
|
1997-04-07 |
2000-07-18 |
Japan Science & Technology Corporation |
Method for quantitatively determining the expression of a gene
|
US5994076A
(en)
|
1997-05-21 |
1999-11-30 |
Clontech Laboratories, Inc. |
Methods of assaying differential expression
|
US20030153541A1
(en)
|
1997-10-31 |
2003-08-14 |
Robert Dudley |
Novel anticholesterol compositions and method for using same
|
ATE338118T1
(de)
|
1997-12-12 |
2006-09-15 |
Univ Western Ontario |
Neues peptid, apoep1.b, zusammensetzungen und verwendungen davon
|
US6004755A
(en)
|
1998-04-07 |
1999-12-21 |
Incyte Pharmaceuticals, Inc. |
Quantitative microarray hybridizaton assays
|
US6048695A
(en)
|
1998-05-04 |
2000-04-11 |
Baylor College Of Medicine |
Chemically modified nucleic acids and methods for coupling nucleic acids to solid support
|
US6087112A
(en)
|
1998-12-30 |
2000-07-11 |
Oligos Etc. Inc. |
Arrays with modified oligonucleotide and polynucleotide compositions
|
US6906069B1
(en)
|
1999-01-08 |
2005-06-14 |
Amgen Inc. |
LXR modulators
|
US6316503B1
(en)
|
1999-03-15 |
2001-11-13 |
Tularik Inc. |
LXR modulators
|
US8257750B2
(en)
|
1999-04-30 |
2012-09-04 |
Kibow Biotech, Inc. |
Calcium carbonate compositions for preventing or treating hyperphosphatemia
|
MXPA01011070A
(es)
|
1999-04-30 |
2003-06-30 |
Arch Dev Corp |
Derivados de esteroides.
|
WO2001066534A2
(en)
|
2000-03-09 |
2001-09-13 |
Abbott Laboratories |
Cyclic and bicyclic diamino histamine-3 receptor antagonists
|
US6716622B2
(en)
|
2000-07-18 |
2004-04-06 |
Uab Research Foundation |
Tissue-specific self-inactivating gene therapy vector
|
WO2002013594A1
(en)
|
2000-08-17 |
2002-02-21 |
Northland Seed & Grain Corp. |
Method for minimizing contamination of crops and products derived therefrom
|
US20030027335A1
(en)
|
2000-09-07 |
2003-02-06 |
Ruley H. Earl |
Genome engineering by cell-permeable DNA site-specific recombinases
|
EP1318976B1
(en)
|
2000-09-18 |
2004-11-24 |
Glaxo Group Limited |
Substituted aminopropoxyaryl derivatives useful as agonists for lxr
|
BR0116845A
(pt)
*
|
2001-01-31 |
2004-02-25 |
Pfizer Prod Inc |
Derivados éter úteis como inibidores de isozimas pde4
|
WO2002062302A2
(en)
|
2001-02-08 |
2002-08-15 |
The University Of Chicago |
Steroidal derivatives
|
PT1392713E
(pt)
|
2001-05-03 |
2008-01-25 |
Univ Chicago |
''agonistas de receptores x hepáticos''
|
US6908934B2
(en)
|
2001-06-11 |
2005-06-21 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
JP2003033179A
(ja)
|
2001-07-05 |
2003-02-04 |
Asahi Kasei Corp |
可逆的遺伝子導入ベクター
|
WO2003031408A2
(en)
|
2001-10-08 |
2003-04-17 |
Eli Lilly And Company |
Tricyclic compounds useful for modulating lxr
|
EP1456187A4
(en)
|
2001-11-15 |
2005-02-09 |
Incyte San Diego Inc |
N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
|
US20050014807A1
(en)
|
2001-11-21 |
2005-01-20 |
Adams Alan D |
Therapeutic compounds for treating dyslipidemic conditions
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
BR0215258A
(pt)
|
2001-12-21 |
2004-12-07 |
Pharmacia Corp |
Moduladores de receptor x de fìgado de tioéter aromático
|
AU2002351412B2
(en)
|
2001-12-21 |
2010-05-20 |
Exelixis Patent Company Llc |
Modulators of LXR
|
ATE521599T1
(de)
|
2001-12-21 |
2011-09-15 |
X Ceptor Therapeutics Inc |
Heterocyclische modulatoren von nukleären rezeptoren
|
WO2003082205A2
(en)
|
2002-03-27 |
2003-10-09 |
Smithkline Beecham Corporation |
Compounds and methods
|
WO2004043939A1
(en)
|
2002-03-27 |
2004-05-27 |
Smithkline Beecham Corporation |
Amide compounds and methods of using the same
|
US7560586B2
(en)
*
|
2002-03-27 |
2009-07-14 |
Smithkline Beecham Corporation |
Acid and ester compounds and methods of using the same
|
AU2003220521A1
(en)
|
2002-03-27 |
2003-10-13 |
Smithkline Beecham Corporation |
Methods of treatment with lxr modulators
|
AU2003222667A1
(en)
|
2002-04-23 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
|
WO2003090869A1
(en)
|
2002-04-23 |
2003-11-06 |
Chugai Seiyaku Kabushiki Kaisha |
Lxr modulators
|
AU2003223684A1
(en)
|
2002-04-23 |
2003-11-10 |
Chugai Seiyaku Kabushiki Kaisha |
Lxr modulators for the treatment of cardiovascular diseases
|
MXPA04011691A
(es)
|
2002-05-24 |
2005-09-12 |
Pharmacia Corp |
Moduladores del receptor x anilino hepaticos.
|
CA2486651A1
(en)
|
2002-05-24 |
2003-12-04 |
Pharmacia Corporation |
Sulfone liver x-receptor modulators
|
US7495004B2
(en)
|
2002-06-17 |
2009-02-24 |
Glaxo Group Limited |
Purine derivatives as liver X receptor agonists
|
TW200401770A
(en)
|
2002-06-18 |
2004-02-01 |
Sankyo Co |
Fused-ring pyrimidin-4(3H)-one derivatives, processes for the preparation and uses thereof
|
DE60332948D1
(de)
|
2002-07-19 |
2010-07-22 |
Althea Technologies Inc |
Strategien zur genexpressionsanalyse
|
WO2004011448A1
(en)
|
2002-07-25 |
2004-02-05 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
DE60328198D1
(de)
|
2002-08-07 |
2009-08-13 |
Novartis Ag |
Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
|
EP1407774A1
(en)
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
US20040110947A1
(en)
|
2002-09-17 |
2004-06-10 |
Pharmacia Corporation |
Aromatic liver X-receptor modulators
|
DE60335911D1
(de)
|
2002-12-20 |
2011-03-10 |
Daiichi Sankyo Co Ltd |
Isochinolinonderivate und deren verwendung als medikamente
|
WO2004072041A1
(en)
|
2003-02-12 |
2004-08-26 |
Care X S.A. |
Tetrahydroquinolines as agonists of liver- x receptors
|
WO2004072042A2
(en)
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivative and their use for modulation of lxr activity
|
WO2004072046A2
(en)
|
2003-02-12 |
2004-08-26 |
Carex S.A. |
Quinoline derivatives and their use for modulation of lxr activity
|
US20040216178A1
(en)
|
2003-03-03 |
2004-10-28 |
Jones Stephen N |
Regulation of mdm2 function
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
GB0316237D0
(en)
|
2003-07-11 |
2003-08-13 |
Astrazeneca Ab |
Therapeutic agents
|
GB0316232D0
(en)
|
2003-07-11 |
2003-08-13 |
Astrazeneca Ab |
Therapeutic agents
|
US20050130919A1
(en)
|
2003-07-18 |
2005-06-16 |
University Of Massachusetts |
Regulatable promoters for synthesis of small hairpin RNA
|
WO2005016277A2
(en)
|
2003-08-12 |
2005-02-24 |
Amgen Inc. |
Arylsulfonamidobenzylic compounds
|
NZ545692A
(en)
|
2003-09-03 |
2009-02-28 |
Kowa Co |
PPAR-activating compound and pharmaceutical composition containing same
|
JP2006193426A
(ja)
|
2003-09-05 |
2006-07-27 |
Sankyo Co Ltd |
置換された縮環ピリミジン−4(3h)−オン化合物
|
RU2006117304A
(ru)
|
2003-10-20 |
2007-12-10 |
Нсджин А/С (Dk) |
Генная терапия болезни паркинсона iv vivo
|
US20050113419A1
(en)
|
2003-10-31 |
2005-05-26 |
Huang Shaei Y. |
Therapeutic compounds for treating dyslipidemic conditions
|
KR20070001922A
(ko)
|
2003-12-12 |
2007-01-04 |
와이어쓰 |
심장혈관질환 치료에 유용한 퀴놀린
|
FR2865736B1
(fr)
|
2004-02-02 |
2006-07-14 |
Synt Em |
Inhibiteurs de l'angiogenese, compositions les contenant et leur utilisation pour le traitement des maladies liees a une deregulation de l'angiogenese
|
JP2007523087A
(ja)
|
2004-02-11 |
2007-08-16 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Lxrモジュレーターとしての化合物および組成物
|
CA2553443C
(en)
|
2004-02-11 |
2012-03-27 |
Irm Llc |
Thiadiazole derivatives and compositions thereof as lxr modulators
|
DK1732892T3
(da)
|
2004-03-26 |
2009-01-05 |
Hoffmann La Roche |
Tetrahydrocarbazoler og derivater
|
CN1950365A
(zh)
|
2004-05-03 |
2007-04-18 |
霍夫曼-拉罗奇有限公司 |
作为肝脏-x-受体调节剂的吲哚基衍生物
|
US20050289659A1
(en)
|
2004-05-18 |
2005-12-29 |
Jacks E T |
Cre-lox based method for conditional RNA interference
|
WO2005113499A1
(ja)
|
2004-05-20 |
2005-12-01 |
Sankyo Company, Limited |
インドール化合物
|
CN1972897A
(zh)
|
2004-06-28 |
2007-05-30 |
霍夫曼-拉罗奇有限公司 |
新型六氟异丙醇衍生物
|
WO2006003923A1
(ja)
|
2004-06-30 |
2006-01-12 |
Sankyo Company, Limited |
置換ベンゼン化合物
|
JP5575357B2
(ja)
|
2004-07-02 |
2014-08-20 |
第一三共株式会社 |
組織因子産生抑制剤
|
JP2008505905A
(ja)
|
2004-07-07 |
2008-02-28 |
メルク エンド カムパニー インコーポレーテッド |
ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
|
CN101213194A
(zh)
|
2004-08-03 |
2008-07-02 |
惠氏公司 |
可用于治疗心血管疾病的吲唑化合物
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US20060178398A1
(en)
|
2004-09-16 |
2006-08-10 |
Adams Alan D |
Therapeutic compounds for treating dyslipidemic conditions
|
CA2581945C
(en)
|
2004-10-01 |
2011-01-18 |
Henrietta Dehmlow |
Hexafluoroisopropanol substituted ether derivatives
|
NZ555325A
(en)
|
2004-10-27 |
2009-07-31 |
Daiichi Sankyo Co Ltd |
Benzene compound having 2 or more substituents
|
CN101087754B
(zh)
|
2004-12-22 |
2012-01-18 |
霍夫曼-拉罗奇有限公司 |
环己烷衍生物
|
JP2008526842A
(ja)
|
2005-01-10 |
2008-07-24 |
アストラゼネカ アクチボラグ |
肝x受容体モジュレーターとしてのイソチアゾール−3(2h)−チオン1,1−ジオキシドのアニリン誘導体
|
BRPI0606388A2
(pt)
|
2005-01-10 |
2009-11-17 |
Astrazeneca Ab |
composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
|
SE0500055D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 3
|
SE0500058D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 5
|
SE0500056D0
(sv)
|
2005-01-10 |
2005-01-10 |
Astrazeneca Ab |
Therapeutic agents 4
|
JP2006232703A
(ja)
|
2005-02-23 |
2006-09-07 |
Dai Ichi Seiyaku Co Ltd |
フェニルエーテル誘導体及びそれを用いた医薬
|
AU2006218661A1
(en)
|
2005-03-01 |
2006-09-08 |
Wyeth |
Cinnoline compounds and their use as liver X receptor modilators
|
WO2006102067A1
(en)
|
2005-03-21 |
2006-09-28 |
Merck & Co., Inc. |
Substituted aryl and heteroaryl derivatives
|
WO2006109633A1
(ja)
|
2005-04-07 |
2006-10-19 |
Daiichi Sankyo Company, Limited |
置換インドール化合物
|
WO2007002559A1
(en)
|
2005-06-27 |
2007-01-04 |
Exelixis, Inc. |
Pyrazole based lxr modulators
|
WO2007022563A1
(en)
|
2005-08-24 |
2007-03-01 |
Graham Scott |
Package with bitter taste aversive agent for infant deterrant
|
NZ567140A
(en)
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Azetidines as MEK inhibitors for the treatment of proliferative diseases
|
US7790745B2
(en)
|
2005-10-21 |
2010-09-07 |
Bristol-Myers Squibb Company |
Tetrahydroisoquinoline LXR Modulators
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US20070093524A1
(en)
|
2005-10-25 |
2007-04-26 |
Wyeth |
5-Lipoxygenase modulators
|
JP2009515904A
(ja)
|
2005-11-14 |
2009-04-16 |
アイアールエム・リミテッド・ライアビリティ・カンパニー |
Lxrモジュレーターとしての化合物および組成物
|
WO2007081335A1
(en)
|
2006-01-12 |
2007-07-19 |
Merck & Co., Inc. |
Therapeutic compounds for treating dyslipidemic conditions
|
DE602007011901D1
(de)
|
2006-03-20 |
2011-02-24 |
Cepep Iii Ab Stockholm |
Ptiden und zellpenetrierenden peptiden gekoppelt a
|
WO2007110755A1
(en)
*
|
2006-03-27 |
2007-10-04 |
Medical Therapies Limited |
Prophylaxis or treatment of cardiovascular inflammation
|
US20100048944A1
(en)
|
2006-07-19 |
2010-02-25 |
Farhad Parhami |
Interactions of hedgehog and liver x receptor signaling pathways
|
WO2008027988A2
(en)
|
2006-08-31 |
2008-03-06 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
|
TW200825054A
(en)
|
2006-10-18 |
2008-06-16 |
Wyeth Corp |
Quinoline compounds
|
US8324367B2
(en)
|
2006-11-03 |
2012-12-04 |
Medtronic, Inc. |
Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
|
EP1925621A1
(en)
*
|
2006-11-27 |
2008-05-28 |
Novartis AG |
Crystalline forms of zoledronic acid
|
ES2380499T3
(es)
|
2006-11-30 |
2012-05-14 |
Kowa Company. Ltd. |
Compuesto de Carbinol sustituido
|
WO2008073825A1
(en)
|
2006-12-08 |
2008-06-19 |
Exelixis, Inc. |
Lxr and fxr modulators
|
JP2008179562A
(ja)
|
2007-01-24 |
2008-08-07 |
Kowa Co |
Lxrアゴニスト
|
US8993628B2
(en)
|
2007-02-23 |
2015-03-31 |
City Of Hope |
Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof
|
BRPI0811091A8
(pt)
|
2007-05-18 |
2015-09-29 |
Wyeth Corp |
Composto, composição farmacêutica, métodos para prevenir ou tratar uma doença, distúrbio ou condição, para aumentar níveis de colesterol hdl no soro em um indivíduo, para reduzir níveis de colestetol ldl no soro em um indivíduo, para aumentar o transporte invertido de colesterol em um indivíduo, e para reduzir a absorção do colesterol em um indivíduo, e, uso de um composto
|
US20090099066A1
(en)
|
2007-06-29 |
2009-04-16 |
Avi Biopharma, Inc. |
Tissue specific peptide conjugates and methods
|
CN103772299A
(zh)
|
2007-08-13 |
2014-05-07 |
霍夫曼-拉罗奇有限公司 |
新型哌嗪酰胺衍生物
|
TW200922582A
(en)
|
2007-08-20 |
2009-06-01 |
Organon Nv |
N-benzyl, N'-arylcarbonylpiperazine derivatives
|
US8039493B2
(en)
|
2007-09-27 |
2011-10-18 |
Hoffmann-La Roche Inc. |
Biaryl sulfonamide derivatives
|
KR101889518B1
(ko)
|
2007-10-04 |
2018-08-17 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
마이크로MIRs
|
US7902147B2
(en)
|
2007-11-05 |
2011-03-08 |
Duke University |
Chronic lymphocytic leukemia prognosis and treatment
|
BRPI0820298A8
(pt)
|
2007-11-09 |
2018-05-08 |
Affitech Res As |
composições e métodos de anticorpos anti-vegf
|
WO2009075836A2
(en)
|
2007-12-10 |
2009-06-18 |
The Brigham And Women's Hospital, Inc. |
Rap variants for drug delivery
|
EP2071509A1
(en)
|
2007-12-13 |
2009-06-17 |
Gemalto SA |
Method and apparatus to mark a document using a combination between guilloches and watermarking, method and apparatus to read previous combination
|
CN101945871A
(zh)
|
2007-12-21 |
2011-01-12 |
惠氏有限责任公司 |
咪唑并[1,2-a]吡啶化合物
|
CN101952257A
(zh)
|
2007-12-21 |
2011-01-19 |
惠氏有限责任公司 |
苯并咪唑化合物
|
BRPI0822239A2
(pt)
|
2007-12-21 |
2015-06-30 |
Wyeth Llc |
Composto de pirazolo[1,5-a] pirimidina
|
WO2009086130A1
(en)
|
2007-12-21 |
2009-07-09 |
Wyeth |
Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
|
JP5511079B2
(ja)
|
2008-02-29 |
2014-06-04 |
興和株式会社 |
2−オキソクロメン誘導体
|
US7951822B2
(en)
|
2008-03-31 |
2011-05-31 |
Kowa Company, Ltd. |
1,3-dihydroisobenzofuran derivatives
|
US8008306B2
(en)
|
2008-04-30 |
2011-08-30 |
Kowa Company, Ltd. |
Quinoline compounds
|
TW201006816A
(en)
|
2008-05-15 |
2010-02-16 |
Organon Nv |
Hexafluoroisopropanol derivatives
|
JP2011525616A
(ja)
|
2008-05-29 |
2011-09-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
共刺激経路の調節に対する患者応答を予測するための方法
|
US8153634B2
(en)
|
2008-05-29 |
2012-04-10 |
Kowa Company, Ltd. |
Carbinol derivatives having cyclic linker
|
US8063088B2
(en)
|
2008-06-11 |
2011-11-22 |
Hoffmann-La Roche Inc. |
Imidazolidine derivatives
|
US20110166079A1
(en)
|
2008-07-01 |
2011-07-07 |
Cognosci, Inc. |
Methods of treating cancer with apoe peptides
|
TW201022230A
(en)
|
2008-08-28 |
2010-06-16 |
Organon Nv |
1-(4-ureidobenzoyl)piperazine derivatives
|
FR2935380B1
(fr)
|
2008-08-29 |
2010-09-10 |
Galderma Res & Dev |
Nouveaux composes hexafluoro-2-biphenyl-isopropanol, modulateurs des recepteurs de type lxrs, leur procede de preparation et leur application comme medicaments en medecine humaine ou veterinaire ainsi qu'en cosmetique.
|
US8613367B2
(en)
|
2008-08-29 |
2013-12-24 |
Saint-Gobain Performance Plastics Corporation |
Sealing assembly and method of making such assembly
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
MX2011003239A
(es)
|
2008-09-26 |
2011-04-28 |
Merck Sharp & Dohme |
Nuevos derivados de bencimidazol ciclicos utiles como agentes anti-diabeticos.
|
CA2742023A1
(en)
|
2008-11-19 |
2010-05-27 |
Wyeth Llc |
Polar quinazolines as liver x receptors ( lxrs ) modulators
|
WO2010101888A2
(en)
|
2009-03-02 |
2010-09-10 |
Biocure Pharma, Llc |
Methods and compositions for treatment of tumor metastasis
|
KR101671046B1
(ko)
|
2009-04-29 |
2016-10-31 |
코와 가부시키가이샤 |
헤테로환 링커를 갖는 카르비놀 화합물
|
EP2435410B1
(en)
|
2009-05-28 |
2017-01-18 |
Exelixis Patent Company LLC |
Lxr modulators
|
CN102482315A
(zh)
|
2009-07-29 |
2012-05-30 |
芝加哥大学 |
肝x受体激动剂
|
KR101636958B1
(ko)
|
2009-09-11 |
2016-07-06 |
주식회사 대웅제약 |
우루소데옥시콜린산-합성하이드로탈사이트-유드라짓 혼성체, 이를 함유하는 약학 조성물 및 그 제조방법
|
TWI513695B
(zh)
|
2009-10-27 |
2015-12-21 |
Merck Sharp & Dohme |
(1,1,1,3,3,3-六氟-2-羥基丙-2-基)苯基衍生物
|
WO2011055391A1
(en)
|
2009-11-09 |
2011-05-12 |
Advinus Therapeutics Private Limited |
Substituted fused pyrimidine compounds, its preparation and uses thereof
|
MX2012005994A
(es)
|
2009-12-04 |
2012-08-08 |
Taisho Pharmaceutical Co Ltd |
Compuestos de 2-piridona.
|
WO2011103175A2
(en)
|
2010-02-16 |
2011-08-25 |
The Regents Of The University Of California |
Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
WO2011130426A2
(en)
|
2010-04-13 |
2011-10-20 |
New York University |
Compositions and methods for treatment of melanoma
|
JP5851400B2
(ja)
|
2010-06-16 |
2016-02-03 |
Lsipファンド運営合同会社 |
大腸腫瘍の検出方法
|
MX2012014801A
(es)
|
2010-07-08 |
2013-01-29 |
Wyeth Llc |
Esteres de quinolina nuevos utiles para el tratamento de transtornos cutaneos.
|
EP2474617A1
(en)
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
US20130004481A1
(en)
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
US20120231457A1
(en)
|
2011-03-10 |
2012-09-13 |
Nikolaos Tezapsidis |
Compositions and methods for assessing a genetic risk of developing late-onset alzheimer's disease (load)
|
EP2688594B1
(en)
|
2011-03-22 |
2016-12-14 |
The Brigham and Women's Hospital, Inc. |
Compositions and their use in the treatment of cancer
|
TW201242953A
(en)
|
2011-03-25 |
2012-11-01 |
Bristol Myers Squibb Co |
Imidazole prodrug LXR modulators
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
US20140274984A1
(en)
|
2011-10-18 |
2014-09-18 |
Affichem |
Acid addition salts of 5alpha-hydroxy-6beta-[2-(1h-imidazol-4-yl)ethylamino]cholestan-3beta-ol
|
CN103054844B
(zh)
|
2011-10-18 |
2014-04-30 |
中国科学院武汉病毒研究所 |
一种gw3965在制备治疗或预防丙型肝炎药物中的应用
|
US9447141B2
(en)
|
2011-11-24 |
2016-09-20 |
(INSERM) (Institut National de la Sante et de la Recherche Medicale) |
Process for the preparation of sterol derivatives
|
SG11201405378VA
(en)
|
2012-03-02 |
2014-09-26 |
Anayaderm Inc |
Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
|
DK2825541T3
(en)
|
2012-03-16 |
2016-10-03 |
Vitae Pharmaceuticals Inc |
LIVER-X-receptor modulators
|
BR112014022780A8
(pt)
|
2012-03-16 |
2021-06-15 |
Vitae Pharmaceuticals Inc |
composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso
|
EP2882496B1
(en)
|
2012-08-13 |
2019-10-09 |
The Rockefeller University |
Treatment and diagnosis of melanoma
|
WO2014144037A1
(en)
|
2013-03-15 |
2014-09-18 |
Bristol-Myers Squibb Company |
Lxr modulators
|
JP6066860B2
(ja)
|
2013-08-05 |
2017-01-25 |
株式会社クボタ |
草刈機
|
WO2015065505A1
(en)
|
2013-10-29 |
2015-05-07 |
Duke University |
Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
|
EP3091970B1
(en)
|
2014-01-10 |
2020-10-28 |
Rgenix, Inc. |
Lxr agonists and uses thereof
|
AP2016009261A0
(en)
|
2014-02-07 |
2016-06-30 |
Global Blood Therapeutics Inc |
Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
CN114099686B
(zh)
|
2014-07-15 |
2024-04-16 |
约翰·霍普金斯大学 |
源自骨髓的抑制细胞的抑制和免疫检查点阻断
|
US20190125745A1
(en)
*
|
2014-12-17 |
2019-05-02 |
Rgenix, Inc. |
Treatment and diagnosis of cancer
|
US20160271149A1
(en)
|
2015-03-16 |
2016-09-22 |
Epinova Therapeutics Corp. |
Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
|
US20170056352A1
(en)
|
2015-08-25 |
2017-03-02 |
Rgenix, Inc. |
PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
US11058700B2
(en)
|
2015-10-28 |
2021-07-13 |
City Of Hope |
Macrocyclic lactones and uses thereof as modulators of purinergic receptors
|
AU2017207291B2
(en)
|
2016-01-11 |
2023-06-15 |
The Rockefeller University |
Methods for the treatment of myeloid derived suppressor cells related disorders
|
EP3430171B1
(en)
|
2016-03-16 |
2022-03-02 |
The Regents of the University of California |
Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
|
WO2017181163A2
(en)
|
2016-04-16 |
2017-10-19 |
Oncocyte Corporation |
Methods and compositions for detection and diagnosis of breast cancer
|
PL3512547T3
(pl)
|
2016-09-14 |
2021-03-08 |
Abbvie Biotherapeutics Inc. |
Przeciwciała anty-pd-1
|
WO2018160178A1
(en)
|
2017-03-01 |
2018-09-07 |
Rgenix, Inc. |
Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
|
KR102641778B1
(ko)
|
2017-03-03 |
2024-02-28 |
인스피르나, 인크. |
향상된 안정성을 갖는 제제
|
CA3078981A1
(en)
|
2017-11-21 |
2019-05-31 |
Rgenix, Inc. |
Polymorphs and uses thereof
|
CN109251974A
(zh)
|
2018-02-14 |
2019-01-22 |
重庆京因生物科技有限责任公司 |
基于poct模式的apoe2和apoe4基因型快速检测试剂盒
|
US20220127680A1
(en)
|
2019-02-28 |
2022-04-28 |
The Rockefeller Universtiy |
Apoe genotyping in cancer prognostics and treatment
|
KR20220022050A
(ko)
|
2019-03-29 |
2022-02-23 |
바이오엔테크 유에스 인크. |
지속적인 임상 이익을 위한 암 바이오마커
|
MX2022007164A
(es)
|
2019-12-13 |
2022-09-12 |
Inspirna Inc |
Sales metálicas y usos de estas.
|